ECE2014 Poster Presentations Diabetes therapy (40 abstracts)
The favourable effects of autologous hematopoietic stem cell transplantation on the immune system in patients with type 1 diabetes
Li Li 1 , Weiqiong Gu 1 , Lei Ye 1 , Minglan Yang 1 , Bin Wan 2 , Jie Hong 1 , Weiqing Wang 1 & Guang Ning 1
1Department of Endocrine and Metabolic diseases, School of Medicine, Ruijin Hospital Affiliated to Shanghai, Jiao-Tong University, Shanghai, China; 2Shanghai Institute of Immunology, Shanghai, China.
Objective: Autologous hematopoietic stem cell transplantation (AHSCT) is a promising treatment to reverse type 1 diabetes (T1D) in patients with significantly improved β-cell function. This study was designed to investigate the potential immunological mechanisms involved.
Design and methods: 18 newly-diagnosed T1D were divided into two groups, the AHSCT group and the insulin therapy group. Blood mononuclear cells (PBMCs) of the patients at the baseline visit and the 12-month follow-up time was collected and cultured. Cell proliferation study was assessed by cell count kit 8 (CCK8), proportion of T cell subsets were analyzed by flow cytometry, and the concentrations of the cytokines in the cell culture supernatants was detected by Procarta Immunoassay Kit. The mRNA expressions of the cytokines were tested by real-time PCR.
Results: i) PBMC showed significant lower proliferation in the AHSCT group and the insulin therapy group compared to the newly-onset group, no difference was found between the two treatments; ii) the proportion of Th1 and Th17 cells decreased in the AHSCT group, but no change was found in the insulin therapy group compared to the newly-onset group; the mRNA expression of IL2 and IFNγ and the supernatants concentrates were significantly reduced in the AHSCT group, while the same levels were found in the insulin therapy group as the newly-onset group; and iii) The proportion of Treg cells in the AHSCT group was close to the newly-onset group, while it changed less in the insulin therapy group, accompanied with the up-regulated mRNA expression and the increased supernatants concentrations of TGF-β in the AHSCT group compared to newly-onset group. No difference was found in the insulin therapy group.
Conclusion: Our results suggested that the AHSCT treatment has induced a favorable immune situation by reducing activity of PBMC proliferation, associated with skewing from Th1/Th17-dominated to increased Treg phenotypes. It might be important to normal immunity and disease control.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more